Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 3/20 | 0.45 |
| ▸ | WNT3A | P56704 | 3/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 4/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5752488 | 0.88 | CETP (0.38) | CTNNB1WNT3ACYP19A1FAAHCFTR | |
| SCHEMBL22657669 | 0.85 | CTNNB1 (0.43) | CTNNB1WNT3ACYP19A1FAAHMRGPRX4 | |
| SCHEMBL80862 | 0.82 | CTNNB1 (0.41) | CTNNB1WNT3ACYP19A1FAAHMRGPRX4 | |
| SCHEMBL2537768 | 0.82 | CYP19A1 (0.43) | CTNNB1WNT3ACYP19A1FAAHMRGPRX4 | |
| SCHEMBL2202262 | 0.81 | CTNNB1 (0.48) | CTNNB1WNT3AFAAHMRGPRX4ROCK2 | |
| SCHEMBL25084169 | 0.80 | ALOX15 (0.55) | KIF11ALOX15ALOX12NPC1RAB9A | |
| SCHEMBL2663369 | 0.80 | CTNNB1 (0.41) | CTNNB1WNT3ACYP19A1FAAHMRGPRX4 | |
| SCHEMBL22657885 | 0.80 | FAAH (0.45) | CTNNB1WNT3ACYP19A1FAAHMRGPRX4 | |
| SCHEMBL31139932 | 0.80 | CTNNB1 (0.41) | CTNNB1WNT3ACYP19A1FAAHMRGPRX4 | |
| SCHEMBL15151309 | 0.80 | CTNNB1 (0.41) | CTNNB1WNT3ACYP19A1FAAHMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1072 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384523-B1 | 2,2-DIFLUORO-5H-[1,3]DIOXOLO[4,5-F]ISOINDOL-7-ONE DERIVATIVES AS PESTICIDES | SYNGENTA CROP PROTECTION AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| US-12595266-B2 | Pesticidally active heterocyclic derivatives with sulfur containing substituents | SYNGENTA CROP PROTECTION AG (CH) | 2026-04-07 | — | — | US | disclosed |
| EP-4218754-B1 | VANZACAFTOR FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12508231-B2 | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-30 | — | — | US | disclosed |
| EP-3880197-B9 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2025-07-02 | — | — | EP | disclosed |
| US-RE50453-E1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| EP-4556008-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250145640-A1 | 2,2-DIFLUORO-5H-[1,3]DIOXOLO[4,5-F]ISOINDOL-7-ONE DERIVATIVES AS PESTICIDES | SYNGENTA CROP PROTECTION AG (CH) | 2025-05-08 | — | — | US | disclosed |
| WO-2025085347-A1 | IL4I1 INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-119403791-A | Isoxazolidine derivatives as herbicidal compounds | 先正达农作物保护股份公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20060052358-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), such as N-(4,5-Diphenyl-thiazol-2-yl)-benzamide, used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-03-09 | — | — | US | disclosed |
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| WO-2005075435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-08-18 | — | — | WO | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | disclosed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
| US-4344960-A | Combating insects and acarids with 3-(2-chloro-3,3,4,4,4-pentafluoro-1-butenyl)-2,2-dimethyl-cyclopropanecarboxylic acid esters | BAYER AKTIENGESELLSCHAFT (DE) | 1982-08-17 | — | — | US | disclosed |
| EP-0040742-A1 | 3-(Chloro-3,3,4,4,4-pentafluoro-1-butenyl)-2,2-dimethylcyclopropanecarboxylic acid esters, process for their preparation and their use in insecticides | BAYER AG (DE) | 1981-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | CTNNB1 1000/4885WNT3A 2252/4885CYP19A1 473/4885 |
| US-20250145640-A1 | 2,2-DIFLUORO-5H-[1,3]DIOXOLO[4,5-F]ISOINDOL-7-ONE DERIVATIVES AS PESTICIDES | DDT, IDO1, ACHE | CTNNB1 2953/4885WNT3A 2082/4885CYP19A1 358/4885 |
| US-12595266-B2 | Pesticidally active heterocyclic derivatives with sulfur containing substituents | CBR3, CBR1, CYCS | CTNNB1 2839/4885WNT3A 3007/4885CYP19A1 1482/4885 |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | TGFBR1, SMAD3, TGFBR2 | CTNNB1 1093/4885WNT3A 1712/4885CYP19A1 4228/4885 |
| US-20060052358-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), such as N-(4,5-Diphenyl-thiazol-2-yl)-benzamide, used for treating genetic disorders; respiratory system disorders | CFTR, ABCC2, ABCC4 | CTNNB1 1285/4885WNT3A 2948/4885CYP19A1 4670/4885 |
| US-12508231-B2 | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | CFTR, MFAP1, CMA1 | CTNNB1 869/4885WNT3A 440/4885CYP19A1 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.